Patent application EP19172053A (EP), filed 2019-04-30
Publication number: EP3733707A1
Title: CAR T-CELLS TARGETING BCMA AND USES THEREOF
Abstract: [0001]    The present application relates to the field of immunotherapy, more particularly to the field of chimeric antigen receptors (CARs). Here, CARs are proposed that are directed against B-cell Maturation Antigen (BCMA, also known as CD269). Also proposed are polynucleotides, vectors encoding the transmembrane polypeptide chains and cells expressing such CARs. These cells are particularly suitable for use in immunotherapy, and strategies to treat diseases such as cancer using these cells are also provided. The engineered immune cells, such as T-cells or natural killer (NK) cells, expressing such CARs are particularly suitable for treating lymphomas, multiple myeloma and leukemia.
IPC codes: A61K  35/    17            A I
A61P  35/    00            A I
C07K  14/   705            A I
C07K  16/    28            A I
Claims: number: 1
text: A chimeric antigen receptor (CAR) comprising an anti-BCMA binding domain, a transmembrane domain, and an intracellular signaling domain, wherein said anti-BCMA binding domain comprises a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 3.
number: 2
text: The CAR of claim 1, wherein said anti-BCMA binding domain further comprises a light chain CDR1 having the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 6.
number: 3
text: The CAR of any one of claim 1 or 2, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 7.
number: 4
text: The CAR of any one of claim 1 to 3, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 8.
number: 5
text: The CAR of any one of claim 1 to 4, wherein there is a G to S and/or a F to Y mutation in CDR1.
number: 6
text: The CAR of any one of claim 1 to 5, wherein there is an I to S mutation at position 7 of CDR2.
number: 7
text: The CAR of any one of claim 1 to 6, wherein there is an V to T mutation in CDR3.
number: 8
text: The CAR of any one of claim 1 to 7, wherein the signaling domain comprises a signaling domain selected from the group consisting of a CD3 zeta domain, a Fc epsilon RI gamma domain and a CD3 epsilon domain.
number: 9
text: The CAR of any one of claim 1 to 8, wherein the signaling domain further comprises a costimulatory domain selected from CD28, 4-1BB, OX40, ICOS, DAP10, DAP12, CD27, and CD2.
number: 10
text: A nucleic acid molecule encoding a CAR according to any one of claims 1 to 9.
number: 11
text: A vector comprising a nucleic acid molecule according to claim 10.
number: 12
text: A cell comprising a CAR according to claim 1 to 9, nucleic acid molecule of claim 10 or vector of claim 11.
number: 13
text: The cell of claim 12 or nucleic acid molecule of claim 10 for use as a medicament.
number: 14
text: The cell of claim 12 or nucleic acid molecule of claim 10 for use in treating cancer.
number: 15
text: The cell or nucleic acid molecule of claim 14, wherein the cancer is selected from leukemia, lymphoma, or multiple myeloma (MM).
number: 16
text: A method of treating cancer in a subject in need thereof, comprising administering to said subject a cell comprising a CAR according to claim 1 to 9, nucleic acid molecule of claim 10 or vector of claim 11.
number: 17
text: The method of claim 15, wherein the cancer is selected from leukemia, lymphoma, or multiple myeloma (MM).
Office action: search_report, dated 2020-11-04
Prior art cited: ref_id: WO2017031104A1
ref_type: patent
severity: background
ref_id: WO2013166051A1
ref_type: patent
severity: background
ref_id: WO2007059782A1
ref_type: patent
severity: background
ref_id: WO2013154760A1
ref_type: patent
severity: background
ref_id: WO2015158671A1
ref_type: patent
severity: background
ref_id: WO2016014789A2
ref_type: patent
severity: background
ref_id: - DRACH ET AL., BLOOD, vol. 92, no. 3, 1998, pages 802 - 809
ref_type: npl
severity: background
ref_id: - GERTZ ET AL., BLOOD, vol. 106, no. 8, 2005, pages 2837 - 2840
ref_type: npl
severity: background
ref_id: - FACON ET AL., BLOOD, vol. 97, no. 6, 2001, pages 1566 - 1571
ref_type: npl
severity: background
ref_id: - HOFMANN ET AL., FRONT IMMUNOL., vol. 9, 2018, pages 835
ref_type: npl
severity: background
ref_id: - GREEN; SAMBROOK: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR LABORATORY PRESS
ref_type: npl
severity: background
ref_id: - AUSUBEL ET AL.: "Current Protocols in Molecular Biology", vol. 114, 2016, JOHN WILEY & SONS
ref_type: npl
severity: background
ref_id: - LAABI ET AL., EMBO J, vol. 11, no. 11, 1992, pages 3897 - 3904
ref_type: npl
severity: background
ref_id: - MADRY ET AL., INT IMMUNOL, vol. 10, no. 11, 1998, pages 1693 - 1702
ref_type: npl
severity: background
ref_id: - JIANG ET AL., CELL MOL IMMUNOL, 2014
ref_type: npl
severity: background
ref_id: - THEMELI ET AL., CELL STEM CELL, 2015
ref_type: npl
severity: background
ref_id: - WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
ref_type: npl
severity: background
ref_id: - HOLT ET AL., TRENDS BIOTECHNOL., vol. 21, no. 11, November 2003 (2003-11-01), pages 484 - 90
ref_type: npl
severity: background
ref_id: - REVETS ET AL., EXPERT OPIN BIOL THER., vol. 5, no. 1, January 2005 (2005-01-01), pages 111 - 24
ref_type: npl
severity: background
ref_id: WO2018085690A1
ref_type: patent
severity: background
ref_id: WO2017031104A1
ref_type: patent
severity: background
ref_id: WO2015158671A1
ref_type: patent
severity: background
ref_id: - SANDRA P SUSANIBAR ADANIYA ET AL: "Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.", AMERICAN JOURNAL OF HEMATOLOGY, vol. 94, no. S1, 25 February 2019 (2019-02-25), pages S28 - S33, XP055631911, DOI: 10.1002/ajh.25428
ref_type: npl
severity: background
ref_id: - MA TIANTIAN ET AL: "Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma", ANNALS OF HEMATOLOGY, BERLIN, DE, vol. 98, no. 4, 28 January 2019 (2019-01-28), pages 813 - 822, XP036733763, ISSN: 0939-5555, [retrieved on 20190128], DOI: 10.1007/S00277-018-03592-9
ref_type: npl
severity: background
ref_id: - ANONYMOUS: "Table 2. Current CAR-T constructs in clinical trials for MM", 26 October 2017 (2017-10-26), XP055518174, Retrieved from the Internet <URL:http://www.multiplemyelomahub.com/media/attachment/a3/a3/table2-cart-cellreview.pdf> [retrieved on 20181023]
ref_type: npl
severity: background
ref_id: WO2015158671
ref_type: patent
severity: background
ref_id: WO2017031104
ref_type: patent
severity: background
ref_id: WO2018085690
ref_type: patent
severity: background
ref_id: - SANDRA P SUSANIBAR ADANIYA ET AL, "Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.", AMERICAN JOURNAL OF HEMATOLOGY, (20190225), vol. 94, no. S1, doi:10.1002/ajh.25428, pages S28 - S33, XP055631911 [I] 1-17 * the whole document *
ref_type: npl
severity: background
ref_id: - MA TIANTIAN ET AL, "Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma", ANNALS OF HEMATOLOGY, BERLIN, DE, vol. 98, no. 4, doi:10.1007/S00277-018-03592-9, ISSN 0939-5555, (20190128), pages 813 - 822, (20190128), XP036733763 [I] 1-17 * the whole document *
ref_type: npl
severity: background
ref_id: - Anonymous, "Table 2. Current CAR-T constructs in clinical trials for MM", (20171026), URL: http://www.multiplemyelomahub.com/media/attachment/a3/a3/table2-cart-cellreview.pdf, (20181023), XP055518174 [I] 1-17 * table 2 *
ref_type: npl
severity: background
Final disposition: pending (2020-11-04)